US Inhaled Insulin Dose Titration Study

NCT00246623

Last updated date
Study Location
Pfizer Investigational Site
Birmingham, Alabama, , United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Diabetes Mellitus, Type 2
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and female, age >= 18 years and <= 80 years, with a diagnosis of type 2 diabetes made at least 6 months prior to study entry, with hemoglobin A1C 7.5-10%

- Currently treated with 2 or more oral antidiabetic agents (sulfonylureas, metformin, and/or thiazolidinediones)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Type 1 diabetes


- Smoking within the past 6 months or significant pulmonary diseases

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Diabetes Mellitus, Type 2To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
NCT00143338
  1. Fresno, California
  2. San Antonio, Texas
ALL GENDERS
30 Years+
years
MULTIPLE SITES
Diabetes Mellitus, Type 2US Inhaled Insulin Dose Titration Study
NCT00246623
  1. Birmingham, Alabama
  2. Los Angeles, California
  3. New Britain, Connecticut
  4. Norwalk, Connecticut
  5. Hollywood, Florida
  6. Atlanta, Georgia
  7. Boise, Idaho
  8. Hayden, Idaho
  9. Baton Rouge, Louisiana
  10. Boston, Massachusetts
  11. Albany, New York
  12. Syracuse, New York
  13. Dallas, Texas
  14. El Paso, Texas
  15. San Antonio, Texas
  16. Bennington, Vermont
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Diabetes Mellitus, Type 2US Inhaled Insulin Therapeutic Choice Questionnaire Study
NCT00139763
  1. Chandler, Arizona
  2. Mesa, Arizona
  3. Phoenix, Arizona
  4. Phoenix, Arizona
  5. Tempe, Arizona
  6. Los Angeles, California
  7. San Diego, California
  8. Colorado Springs, Colorado
  9. Newark, Delaware
  10. Wilmington, Delaware
  11. Washington, District of Columbia
  12. Jacksonville, Florida
  13. Jacksonville, Florida
  14. Hayden, Idaho
  15. Nampa, Idaho
  16. Gurnee, Illinois
  17. Elkton, Maryland
  18. Detroit, Michigan
  19. Minneapolis, Minnesota
  20. St. Louis, Missouri
  21. Omaha, Nebraska
  22. Margate City, New Jersey
  23. Santa Fe, New Mexico
  24. New York, New York
  25. Morehead City, North Carolina
  26. Salisbury, North Carolina
  27. Statesville, North Carolina
  28. Winston-Salem, North Carolina
  29. Cincinnati, Ohio
  30. Portland, Oregon
  31. Portland, Oregon
  32. Orangeburg, South Carolina
  33. Simpsonville, South Carolina
  34. Arlington, Texas
  35. Dallas, Texas
  36. Madisonville, Texas
  37. San Antonio, Texas
  38. Bennington, Vermont
  39. Virginia Beach, Virginia
  40. Spokane, Washington
  41. Tacoma, Washington
  42. Milwaukee, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Diabetes Mellitus, Type 212 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin
NCT00473525
  1. Birmingham, Alabama
  2. Gilbert, Arizona
  3. Phoenix, Arizona
  4. Phoenix, Arizona
  5. Jonesboro, Arkansas
  6. Little Rock, Arkansas
  7. Carmichael, California
  8. Chula Vista, California
  9. Fair Oaks, California
  10. Los Angeles, California
  11. National City, California
  12. Paramount, California
  13. Roseville, California
  14. Sacramento, California
  15. DeFuniak Springs, Florida
  16. Destin, Florida
  17. Jacksonville, Florida
  18. New Port Richey, Florida
  19. New Port Richey, Florida
  20. Palm Harbor, Florida
  21. West Palm Beach, Florida
  22. Atlanta, Georgia
  23. Conyers, Georgia
  24. Chicago, Illinois
  25. Skokie, Illinois
  26. Skokie, Illinois
  27. Wheeling, Illinois
  28. Lexington, Kentucky
  29. Lexington, Kentucky
  30. Brockton, Massachusetts
  31. Worcester, Massachusetts
  32. Ann Arbor, Michigan
  33. Canton, Michigan
  34. Flint, Michigan
  35. Biloxi, Mississippi
  36. Picayune, Mississippi
  37. St. Louis, Missouri
  38. Omaha, Nebraska
  39. Las Vegas, Nevada
  40. Las Vegas, Nevada
  41. Las Vegas, Nevada
  42. Trenton, New Jersey
  43. Cary, North Carolina
  44. Raleigh, North Carolina
  45. Raleigh, North Carolina
  46. Marion, Ohio
  47. Oklahoma City, Oklahoma
  48. Oklahoma City, Oklahoma
  49. Carnegie, Pennsylvania
  50. East Providence, Rhode Island
  51. Bartlett, Tennessee
  52. Collierville, Tennessee
  53. Kingsport, Tennessee
  54. Dallas, Texas
  55. Houston, Texas
  56. Houston, Texas
  57. Houston, Texas
  58. Houston, Texas
  59. Irving, Texas
  60. San Antonio, Texas
  61. San Antonio, Texas
  62. Richmond, Virginia
  63. Virginia Beach, Virginia
  64. Milwaukee, Wisconsin
  65. Bogota, Cundinamarca
  66. Bogota, Cundinamarca
  67. Floridablanca, Santander
  68. Berlin,
  69. Giengen,
  70. Hamburg,
  71. Muenchen,
  72. Roma,
  73. Santiago de Compostela, La Coruña
  74. Alcala de Henares, Madrid
  75. Valencia,
  76. Valencia,
  77. Goteborg,
  78. Malmo,
  79. Stockholm,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE US Inhaled Insulin Dose Titration Study
Official Title  ICMJE A Randomized, Open-Label, Multicenter Study Assessing the Effects of Forced Exubera Dose Titration on Glycemic Control in Patients With Suboptimally Controlled Type 2 Diabetes on Two or More Oral Antidiabetic Agents
Brief Summary This study will examine how to dose Exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. This study should show that a large number of patients enrolled in the study can reach the target Hemoglobin A1C levels (7% or less) that have been set by the American Diabetes Association (ADA). Target goals should be achieved by adjusting the Exubera dose either weekly or twice weekly. Patients will also receive nutritional counseling and diabetes education as part of the study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Diabetes Mellitus, Type 2
Intervention  ICMJE
  • Drug: Exubera (inhaled insulin)
  • Procedure: 8-point glucose diary (to assess pre- and post prandial glucoses)
  • Procedure: Meal Tolerance Test
  • Procedure: 24-hour continuous glucose monitoring (at select sites)
  • Procedure: Pulmonary Function Testing
  • Procedure: Hypoglycemic Event Monitoring
  • Procedure: Laboratory Assessments
  • Behavioral: Nutritional Counseling and Diabetes Education
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: October 28, 2005)
120
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE March 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and female, age >= 18 years and <= 80 years, with a diagnosis of type 2 diabetes made at least 6 months prior to study entry, with hemoglobin A1C 7.5-10%
  • Currently treated with 2 or more oral antidiabetic agents (sulfonylureas, metformin, and/or thiazolidinediones)

Exclusion Criteria:

  • Type 1 diabetes
  • Smoking within the past 6 months or significant pulmonary diseases
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00246623
Other Study ID Numbers  ICMJE A2171067
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Sanofi
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP